CR20200117A - Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use - Google Patents
Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of useInfo
- Publication number
- CR20200117A CR20200117A CR20200117A CR20200117A CR20200117A CR 20200117 A CR20200117 A CR 20200117A CR 20200117 A CR20200117 A CR 20200117A CR 20200117 A CR20200117 A CR 20200117A CR 20200117 A CR20200117 A CR 20200117A
- Authority
- CR
- Costa Rica
- Prior art keywords
- angptl3
- rnai agents
- compositions
- angiopoietin
- methods
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, able to inhibit Angiopoietin-like 3 (also called ANGPTL3, ANGPL3, angiopoietin-like protein 3) gene expression, and compositions that include ANGPTL3 RNAi agents. Also disclosed are methods of use of ANGPTL3 RNAi agents and compositions. The ANGPTL3 RNAi agents disclosed herein may be conjugated to targeting ligands to facilitate the delivery to cells, including to hepatocytes. Pharmaceutical compositions that include one or more ANGPTL3 RNAi agents, optionally with one or more additional therapeutics, are described. Deliver}' of the ANGPTL3 RNAi agents in vivo provides for inhibition of ANGPTL3 gene expression, and can result in lower triglycerides and. or cholesterol levels in the subject. The RNAi agents can be used in methods of treatment of ANGPTL3 -related diseases and disorders, including cardiometabolic diseases such as hypertriglyceridemia and hyperlipidemia.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762558819P | 2017-09-14 | 2017-09-14 | |
US201762583919P | 2017-11-09 | 2017-11-09 | |
US201862651284P | 2018-04-02 | 2018-04-02 | |
PCT/US2018/050848 WO2019055633A1 (en) | 2017-09-14 | 2018-09-13 | Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20200117A true CR20200117A (en) | 2020-04-18 |
Family
ID=70917966
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20200117A CR20200117A (en) | 2017-09-14 | 2018-09-13 | Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use |
Country Status (1)
Country | Link |
---|---|
CR (1) | CR20200117A (en) |
-
2018
- 2018-09-13 CR CR20200117A patent/CR20200117A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020500309A1 (en) | Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use | |
PH12020500332A1 (en) | Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3) | |
ZA202106265B (en) | Compositions and methods for inhibiting gene expression of lpa | |
PH12021550423A1 (en) | Rnai agents for inhibiting expression of 17beta-hsd type 13- (hsd17b13), compositions thereof, and methods of use | |
ZA202002094B (en) | Trispecific proteins and methods of use | |
MX2021005389A (en) | Lipid nanoparticle formulations. | |
WO2016106404A3 (en) | Methods and compositions for treating malignant tumors associated with kras mutation | |
WO2015106128A3 (en) | Rnai agents modified at the 4'-c-position | |
EP4332576A3 (en) | Synergistic enhancement of the delivery of nucleic acids via blended formulations | |
IN2015DN00376A (en) | ||
EP4124346A3 (en) | Compositions and methods for treating diseases | |
AU2018264384A1 (en) | Solid forms of berberine ursodeoxycholate and compositions and methods thereof | |
EA201792103A1 (en) | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HIF2ALPH GENES | |
EA033448B1 (en) | Modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders | |
MX2021008261A (en) | Rnai agents for inhibiting expression of hif-2 alpha (epas1), compositions thereof, and methods of use. | |
PH12019502660A1 (en) | RNAi AGENTS FOR INHIBITING EXPRESSION OF ALPHA-ENaC AND METHODS OF USE | |
CR20200117A (en) | Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use | |
EA202090717A1 (en) | RNAi MEANS AND COMPOSITIONS FOR INHIBITING EXPRESSION OF ANGIOPOETIN-LIKE PROTEIN 3 (ANGPTL3) AND METHODS OF APPLICATION | |
EA202090687A1 (en) | RNAi AGENTS AND COMPOSITIONS FOR INHIBITING EXPRESSION OF APOLIPOPROTEIN C-III (APOC3) | |
WO2016018454A3 (en) | Compositions and methods employing bcl2 and bcl2 family members | |
EA202190800A1 (en) | RNA AGENTS FOR INHIBITING EXPRESSION 17beta-HSD TYPE 13 (HSD17B13), THEIR COMPOSITIONS AND METHODS OF APPLICATION |